Abstract
Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Current Pharmaceutical Design
Title:How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Volume: 19 Issue: 21
Author(s): Vasilios Tsimihodimos, Matilda Florentin and Moses S. Elisaf
Affiliation:
Keywords: Aldosterone, angiotensin, dyslipidemia, fibrates, hypertension, new-onset diabetes, prediabetes, statins.
Abstract: Type 2 diabetes mellitus (T2DM) is a serious health problem with epidemic proportions and associated with high cardiovascular morbidity and mortality. Thus, the prevention or at least delaying the onset of T2DM is imperative. Subjects with impaired glucose metabolism (prediabetes) are highly likely to develop overt T2DM. Treatment of accompanied cardiovascular risk factors, such as hypertension and dyslipidemia, in these patients is frequently complicated as it can impair the already altered glucose homeostasis. This review discusses the pathophysiology of lipid disorders and hypertension in prediabetes along with the effects of lipid modifying and antihypertensive drugs in glucose/insulin metabolism. A critical overview and suggestions of different treatment options for prediabetic patients with dyslipidemia and/or hypertension are also presented.
Export Options
About this article
Cite this article as:
Tsimihodimos Vasilios, Florentin Matilda and S. Elisaf Moses, How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?, Current Pharmaceutical Design 2013; 19 (21) . https://dx.doi.org/ 10.2174/13816128113199990304
DOI https://dx.doi.org/ 10.2174/13816128113199990304 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis
Current Drug Delivery Nanotechnology and Atherosclerosis Imaging: Emerging Diagnostic and Therapeutic Applications
Recent Patents on Cardiovascular Drug Discovery Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science The Role of Continuous Positive Airway Pressure in the Treatment of Hypertension in Patients with Obstructive Sleep Apnea-Hypoapnea Syndrome: A Review of Randomized Trials
Reviews on Recent Clinical Trials Relation of Neck Circumference with Total Body Fat and BMI
Current Nutrition & Food Science History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome)
Current Pharmaceutical Design Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Antioxidant Properties and Medicinal Uses of Some Crataegus Spp. (Hawthorn) Including <i>C. meyeri</i> and <i>C. pontica</i>
Current Nutrition & Food Science Parathyroid Hypertension: A Rare, but Curable form of Secondary Hypertension
Current Hypertension Reviews Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design An Overview on Cardiovascular Protective Effects of Catechins
Cardiovascular & Hematological Disorders-Drug Targets Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Plant Extracts and their Secondary Metabolites as Modulators of Kinases
Current Topics in Medicinal Chemistry The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
Current Cardiology Reviews Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials
CNS & Neurological Disorders - Drug Targets